PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.32
-0.05 (-2.11%)
▼
5d:
-3.33%
30d:
+0.0%
90d:
+9.43%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PLX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PLX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.32, which is considered fair relative to its 30-day fair value range of $2.30 to $2.39. From a valuation perspective, the stock is trading at a premium (Forward PE: 46.4) compared to its historical average (30.6). At these levels, the market is pricing in 14.9% annual earnings growth.
Technical Outlook: Technically, PLX is showing sideways momentum. Immediate support is located at $2.20, while resistance sits at $2.48.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.00 (+374.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PLX is showing sideways momentum. Immediate support is located at $2.20, while resistance sits at $2.48.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.00 (+374.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.30 -
$2.39
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 374.1% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 14.9% growth with 233.7% revenue growth
Trading Range Analysis
30-Day Trading Range
$2.30 -
$2.39
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.20
Resistance Level
$2.48
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
46.40
Wall Street Target
$11.00
(+374.1%)
Revenue Growth (YoY)
233.7%
Earnings Growth (YoY)
-1.0%
Profit Margin
20.1%
Valuation Premium vs History
+14.9% premium
PE vs Historical
46.4 vs 30.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.9%
(market-implied from PE analysis)
1-Year Target
$2.67
(+15%)
2-Year Target
$3.06
(+32%)
3-Year Target
$3.52
(+52%)
3-Yr Target (if PE normalizes)
(PE: 46→31)
PE COMPRESSION
$2.32
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.4, Growth: -74.4%)
$1.69
(+-27%)
Base:
(SPY PE: 20.7, Growth: -74.4%)
$0.76
(-67%)
Bear:
(PE: 17.6, Growth: -74.4%)
$0.64
(-72%)
📈
Valuation based on Current Earnings
Trailing PE: 12.47 | Current EPS (TTM): $0.19
Bull Case
$1.30
(-44%)
Analyst growth -50.0%, PE expands to 13.7
Base Case
$1.19
(-49%)
Market implied -50.0%, PE stable at 12.5
Bear Case
$1.61
(-31%)
Severe decline -20.0%, PE contracts to 10.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 04, 2026 5:55 AM ET
Data refreshes hourly during market hours. Next update: 6:55 AM
Data refreshes hourly during market hours. Next update: 6:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
